Filed by the Registrant ☒
|
| |
Filed by a Party other than the Registrant ☐
|
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
DYNAVAX TECHNOLOGIES CORPORATION
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
☒
|
| |
No fee required.
|
|||
|
| |
|
| |
|
☐
|
| |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|||
|
| |
|
| |
|
|
| |
1.
|
| |
Title of each class of securities to which transaction applies:
|
|
| |
|
| |
|
|
| |
2.
|
| |
Aggregate number of securities to which transaction applies:
|
|
| |
|
| |
|
|
| |
3.
|
| |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
| |
|
| |
|
|
| |
4.
|
| |
Proposed maximum aggregate value of transaction:
|
|
| |
|
| |
|
|
| |
5.
|
| |
Total fee paid:
|
|
| |
|
| |
|
☐
|
| |
Fee paid previously with preliminary materials.
|
|||
|
| |
|
| |
|
☐
|
| |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|||
|
| |
|
| |
|
|
| |
6.
|
| |
Amount Previously Paid:
|
|
| |
|
| |
|
|
| |
7.
|
| |
Form, Schedule or Registration Statement No.:
|
|
| |
|
| |
|
|
| |
8.
|
| |
Filing Party:
|
|
| |
|
| |
|
|
| |
9.
|
| |
Date Filed:
|
|
| |
|
| |
|
1.
|
To elect our three nominees for Class III directors to hold office until the 2024 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
|
2.
|
To approve the amendment and restatement of the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 1,000,000.
|
3.
|
To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
|
4.
|
To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
|
5.
|
To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
|
| |
By Order of the Board of Directors
|
|
| |
|
|
| |
Kelly MacDonald
|
|
| |
Chief Financial Officer
|
•
|
by telephone: call 1-800-579-1639 free of charge and follow the instructions;
|
•
|
by Internet: go to www.proxyvote.com and follow the instructions; or
|
•
|
by e-mail: send an e-mail message to sendmaterial@proxyvote.com. Please send a blank e-mail and insert the 16-Digit Control Number located in your Notice in the subject line.
|
1.
|
To elect our three nominees for Class III directors to hold office until the 2024 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
|
2.
|
To approve the amendment and restatement of the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 1,000,000.
|
3.
|
To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
|
4.
|
To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
|
•
|
To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.
|
•
|
To vote by phone, call 1-800-690-6903 free of charge and follow the recorded instructions. You will be asked to provide the control number from the Notice. Your telephone vote must be received by 11:59 p.m., Eastern Time on May 27, 2021 to be counted.
|
•
|
To vote through the Internet before the meeting, go to www.proxyvote.com and follow the on-screen instructions to complete an electronic proxy card. You will be asked to provide the control number from the Notice. Your Internet vote must be received by 11:59 p.m., Eastern Time on May 27, 2021 to be counted.
|
•
|
To vote through the Internet during the meeting, please visit www.virtualshareholdermeeting.com/DVAX2021 and have available the 16-digit control number included in your Notice.
|
•
|
Proposal 1: “For” election of our three nominees as Class III directors;
|
•
|
Proposal 2: “For” approval of the amendment and restatement of the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 1,000,000;
|
•
|
Proposal 3: “For” advisory approval of executive compensation; and
|
•
|
Proposal 4: “For” ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
|
•
|
You may submit another properly completed proxy card with a later date.
|
•
|
You may submit a later-dated vote by telephone by calling 1-800-690-6903. You will need the 16-digit control number included on your Notice or your proxy card (if you received a printed copy of the proxy materials). Votes submitted by telephone must be received by 11:59 p.m., Eastern Time on May 27, 2021 to be counted.
|
•
|
You may grant a subsequent proxy through the Internet. You will need the 16-digit control number included on your Notice or your proxy card (if you received a printed copy of the proxy materials).
|
•
|
You may send a timely written notice that you are revoking your proxy to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2100 Powell Street, Suite 900, Emeryville, California 94608.
|
•
|
You may virtually attend the Annual Meeting and vote by Internet by visiting www.virtualshareholdermeeting.com/DVAX2021. To attend the Annual Meeting, you will need the 16-digit control number included in your Notice, on your proxy card or on the instructions that accompanied your proxy materials. Simply attending the meeting will not, by itself, revoke your proxy.
|
•
|
Proposal 1: to elect our three nominees for Class III directors, the three nominees receiving the most “For” votes from the holders of shares present (either in person or represented by proxy) and cast for the election of directors will be elected. Only votes “For” will affect the outcome of the vote; “Withhold” votes will have no effect on the outcome of the vote. However, if a nominee receives a greater number of “Withhold” votes than “For” votes, such nominee will submit his or her offer of resignation for consideration by our Nominating and Corporate Governance Committee in accordance with our Majority Vote Policy discussed in more detail in the section entitled “Corporate Governance – Majority Vote Policy” in this proxy statement.
|
•
|
Proposal 2: to approve an amendment and restatement of the 2014 ESPP to increase the aggregate number of shares of common stock authorized for issuance under the 2014 ESPP by 1,000,000, such amendment and restatement must receive “For” votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select “Abstain,” it will have the same effect as an “Against” vote. Broker non-votes will have no effect.
|
•
|
Proposal 3: to approve, on an advisory basis, the 2020 compensation of the Company’s named executive officers, such advisory approval must receive “For” votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will have no effect.
|
•
|
Proposal 4: to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for our fiscal year ending December 31, 2021, such ratification must receive “For” votes from the holders of a majority of shares present (either in person or by proxy) and entitled to vote on the matter at the meeting. If you return your proxy and select “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will have no effect. However, as Proposal 4 is considered a “routine” matter, we do not expect to receive any broker non-votes.
|
|
Name
|
| |
Age
|
| |
Position
|
|
|
Francis R. Cano, Ph.D.
|
| |
76
|
| |
Director
|
|
|
Julie Eastland
|
| |
56
|
| |
Director
|
|
|
Andrew Hack, M.D., Ph.D.
|
| |
47
|
| |
Director
|
|
|
Daniel L. Kisner, M.D.
|
| |
74
|
| |
Director
|
|
|
Brent MacGregor
|
| |
57
|
| |
Director
|
|
|
Peter R. Paradiso, Ph.D.
|
| |
70
|
| |
Director
|
|
|
Peggy V. Phillips
|
| |
67
|
| |
Director
|
|
|
Natale Ricciardi
|
| |
72
|
| |
Director
|
|
|
Ryan Spencer
|
| |
43
|
| |
Director and Chief Executive Officer
|
|
•
|
Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may be issued under the Amended 2014 ESPP will be 1,850,000 shares, which is an increase of 1,000,000 shares over the current maximum number of shares of our common stock that may be issued under the 2014 ESPP.
|
|
Name and Position
|
| |
Number of Shares
|
|
|
Ryan Spencer
CEO and Director
|
| |
7,848
|
|
|
David F. Novack
President and Chief Operating Officer
|
| |
8,671
|
|
|
Michael Ostrach
Former Senior Vice President, Chief Financial Officer and Chief Business Officer
|
| |
—
|
|
|
Robert Janssen, M.D.
Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs
|
| |
4,086
|
|
|
All current executive officers as a group
|
| |
20,605
|
|
|
All current directors who are not executive officers as a group
|
| |
—
|
|
|
Each nominee for election as a director:
|
| |
|
|
|
Francis R. Cano, Ph.D.
|
| |
—
|
|
|
Peter Paradiso, Ph.D.
|
| |
—
|
|
|
Peggy V. Phillips
|
| |
—
|
|
|
Each associate of any executive officers, current directors or director nominees
|
| |
—
|
|
|
Each other person who received or is to receive 5% of purchase rights
|
| |
—
|
|
|
All employees, including all current officers who are not executive officers, as a group
|
| |
677,728
|
|
|
Plan Category
|
| |
Number of
securities to
be issued upon exercise
of outstanding options,
warrants and rights
|
| |
Weighted-average
exercise price of
outstanding
options, warrants
and rights(3)
|
| |
Number
of securities remaining
available for future
issuance under
equity compensation
plans (excluding
securities reflected in
the first column)
|
|
|
Equity compensation plans approved by security holders:
|
| |
|
| |
|
| |
|
|
|
2011 Equity Incentive Plan
|
| |
3,426,009
|
| |
$18.64
|
| |
—
|
|
|
2014 Employee Stock Purchase Plan(1)
|
| |
—
|
| |
$—
|
| |
255,583
|
|
|
2018 Equity Incentive Plan
|
| |
6,721,119
|
| |
$6.66
|
| |
8,349,853
|
|
|
Equity compensation plans not approved by security holders:
|
| |
|
| |
|
| |
|
|
|
2017 Inducement Award Plan(2)
|
| |
151,777
|
| |
$17.55
|
| |
—
|
|
|
Total:
|
| |
10,298,905
|
| |
$11.57
|
| |
8,605,436
|
|
(1)
|
As of December 31, 2020, an aggregate of 255,583 shares remained available for future issuance under the 2014 Employee Stock Purchase Plan, and as of April 6, 2021, up to a maximum of 151,667 shares may be purchased in the current purchase period.
|
(2)
|
In order to induce qualified individuals to join our Company, on November 28, 2017, our Board adopted the 2017 Inducement Award Plan, or the 2017 Inducement Plan, which provided for the issuance of up to 1,200,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2017 Inducement Plan was not required under Nasdaq Marketplace Rule 5635(c)(4). Upon the effectiveness of the 2018 Equity Incentive Plan, no additional awards were granted under the 2017 Inducement Plan. All shares currently subject to awards outstanding under the 2017 Inducement Plan, which awards expire or are forfeited, are included in the reserve for the 2018 Equity Incentive Plan to the extent such shares would otherwise return to such plan. Awards granted under the 2017 Inducement Plan have a term of 10 years. Exercisability, option price and other terms are determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2017 Inducement Plan generally vest over a period of four years, with the exception of performance-based awards which will vest upon achievement of certain performance conditions.
|
(3)
|
1,794,153 shares subject to restricted stock units (RSUs) were granted under the 2011 Equity Incentive Plan and 2018 Equity Incentive Plan. Since these awards have no exercise price, they are not included in the weighted-average exercise price calculation.
|
|
|
| |
Fiscal Year Ended
|
| |||
|
|
| |
2020
|
| |
2019
|
|
|
Audit Fees(1)
|
| |
$1,729,615
|
| |
$1,475,391
|
|
|
Audit Related Fees
|
| |
—
|
| |
—
|
|
|
Tax Fees(2)
|
| |
72,167
|
| |
46,550
|
|
|
All Other Fees(3)
|
| |
2,000
|
| |
1,995
|
|
|
Total Fees
|
| |
$1,803,782
|
| |
$1,523,936
|
|
(1)
|
Audit fees include fees for the audit of our consolidated financial statements and interim reviews of our quarterly financial statements, including compliance with the provisions of Section 404 of the Sarbanes-Oxley Act as well as fees related to registration statements, consents and other services related to SEC matters. In each of 2019 and 2020, audit fees included fees related to a comfort letter in connection with an equity offering.
|
(2)
|
Tax fees include Section 382 study and other tax advisory services.
|
(3)
|
All other fees represent subscription fees for an online accounting research tool and related database.
|
|
Name
|
| |
Age
|
| |
Position
|
|
|
Ryan Spencer(1)
|
| |
43
|
| |
Chief Executive Officer and Director
|
|
|
David F. Novack
|
| |
59
|
| |
President and Chief Operating Officer
|
|
|
Kelly MacDonald
|
| |
37
|
| |
Senior Vice President, Chief Financial Officer
|
|
|
Robert Janssen, M.D.
|
| |
67
|
| |
Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs
|
|
(1)
|
Please see “Proposal 1 – Election of Directors” in this proxy statement for more information about Mr. Spencer.
|
•
|
Ryan Spencer, Chief Executive Officer and Director;
|
•
|
David F. Novack, President and Chief Operating Officer;
|
•
|
Michael S. Ostrach, former Senior Vice President, Chief Financial Officer and Chief Business Officer; and
|
•
|
Robert Janssen, M.D., Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs; and
|
What we do
|
| |
What we do not do
|
||||||
☒
|
| |
Design executive compensation program to align pay with performance
|
| |
☒
|
| |
No excessive change in control or severance payments (no cash severance multiplier greater than 1.75x base + target bonus)
|
☒
|
| |
Prohibit hedging and discourage pledging by executive officers and directors (no pledging occurred in 2020)
|
| |
☒
|
| |
No repricing of underwater stock options without stockholder approval
|
☒
|
| |
Grant equity awards with performance-based vesting of greater than one year
|
| |
☒
|
| |
No tax gross-ups
|
☒
|
| |
Conduct an annual say-on-pay vote
|
| |
☒
|
| |
No excessive perquisites
|
☒
|
| |
Seek input from, listen to and respond to stockholders
|
| |
☒
|
| |
No guaranteed bonuses
|
•
|
Link a significant proportion of pay with performance and the achievement of our strategic goals;
|
•
|
Align our executives’ interests with those of our stockholders through equity compensation;
|
•
|
Achieve a mix of overall compensation that is competitive in the industry in which we compete for executive talent; and
|
•
|
Recognize individual contributions, teamwork and corporate performance.
|
•
|
Peer and Industry Data – The Compensation Committee uses peer and industry data provided by its consultant, Arnosti Consulting Inc. (“Arnosti”), as a reference in setting base salaries and target cash compensation, determining appropriate levels and mix of equity compensation and determining the type and portion of compensation tied to performance goals.
|
•
|
Annual Performance Reviews – The Chair of the Compensation Committee conducts annual performance reviews of our CEO taking into consideration feedback obtained during the course of the
|
•
|
CEO Recommendations – The Compensation Committee seeks input from our CEO for setting the salary and target cash compensation levels for the other NEOs, and also for purposes of setting annual performance metrics and target amounts under our annual incentive program.
|
•
|
The provision of other services to the Company;
|
•
|
The amount of fees paid to Arnosti by the Company;
|
•
|
Arnosti’s policies and procedures that are designed to prevent conflicts of interest;
|
•
|
Any business or personal relationship of Arnosti or the individual compensation advisors employed by Arnosti with an executive officer of the Company; and
|
•
|
Any Company stock owned by Arnosti or the individual compensation advisors contracted by Arnosti.
|
•
|
Provided recommendations to the Compensation Committee on refining our peer group;
|
•
|
Provided general information concerning executive compensation trends and developments;
|
•
|
Reviewed and analyzed compensation levels of our NEOs in comparison to those of our peer companies;
|
•
|
Provided the Board with a review of competitive data from the peer group on Board compensation; and
|
•
|
Reviewed the Compensation Discussion and Analysis for inclusion in our proxy statement.
|
•
|
Were commercial-stage companies having already filed for an IND;
|
•
|
Were pure-play vaccine developers; and
|
•
|
Had their own manufacturing operations, where possible.
|
•
|
| |
Acorda Therapeutics, Inc.
|
•
|
| |
Adamas Pharmaceuticals Inc.
|
•
|
| |
Akebia Therapeutics, Inc.
|
•
|
| |
AMAG Pharmaceuticals, Inc.
|
•
|
| |
Ardelyx, Inc.
|
•
|
| |
Biocryst Pharmaceuticals, Inc.
|
•
|
| |
ChemoCentryx, Inc.
|
•
|
| |
Clovis Oncology, Inc.
|
•
|
| |
Eagle Pharmaceuticals, Inc.
|
•
|
| |
Five Prime Therapeutics Inc.
|
•
|
| |
Heron Therapeutics, Inc.
|
•
|
| |
Immunogen, Inc.
|
•
|
| |
Karyopharm Therapeutics, Inc.
|
•
|
| |
Macrogenics, Inc.
|
•
|
| |
Momenta Pharmaceuticals, Inc.
|
•
|
| |
Novavax, Inc.
|
•
|
| |
Portola Pharmaceuticals, Inc.
|
•
|
| |
Puma Biotechnology, Inc.
|
•
|
| |
Retrophin, Inc.
|
•
|
| |
Rigel Pharmaceuticals, Inc.
|
•
|
| |
Theravance Biopharma, Inc.
|
|
Element
|
| |
Purpose
|
| |
Key Characteristics
|
|
|
Base Salary
|
| |
Provides a fixed level of compensation for performing the essential elements of the job; gives executives a degree of certainty in light of having a majority of their compensation at risk.
|
| |
Fixed compensation that is reviewed annually and adjusted if and when appropriate; reflects each NEO’s performance, experience, skills, level of responsibility and the breadth, scope and complexity of the position as well as the competitive marketplace for executive talent specific to our industry.
|
|
|
Element
|
| |
Purpose
|
| |
Key Characteristics
|
|
|
Annual Cash Incentive Program
|
| |
Motivates executive officers to achieve corporate and individual business goals, which we believe increase stockholder value, while providing flexibility to respond to opportunities and changing market conditions.
|
| |
Annual cash incentive based on corporate and individual performance compared to pre-established goals. For 2020, each of our Chief Executive Officer’s and President and Chief Operating Officer’s annual incentive was based on corporate goals only.
Corporate goals focus on overarching objectives for the Company which will support long-term value, while individual objectives are aligned to corporate objectives and other strategic priorities of the Company.
Corporate goals are aligned with our business strategy and weighted by relative importance so that overall corporate achievement can be objectively measured.
|
|
|
Long-Term Equity Incentive Awards (Stock Options)
|
| |
Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long term.
|
| |
Stock options with an exercise price equal to the fair market value on the date of grant vesting over three years; the ultimate value realized, if any, depends on the appreciation of our common stock price following grant. If our stock price does not appreciate, there is no value realized. In determining the aggregate size of equity grants in any given year, the Compensation Committee generally considers the same factors described above under “Base Salaries” as well as the criticality of the executive to the long-term achievement of corporate goals.
In 2020, we targeted roughly 75% of our NEO’s annual grant value to be time-based options.
From time to time, we may also use special grants of stock options to encourage retention or for other purposes as determined by the Board. No such special stock options were granted to NEOs in 2020.
|
|
|
Long-Term Equity Incentives (RSUs)
|
| |
Motivates executive officers to achieve our corporate objectives by tying compensation to the performance of our common stock over the long term; provides motivation for our executive officers to remain with the Company by mitigating swings in incentive values during periods when market volatility weighs on our stock price.
|
| |
Restricted stock unit awards may vest based on continued service over a specified period of time and/or achievement of performance goals; the ultimate value realized varies with our common stock price. During 2020 we only granted performance RSUs to NEOs. We did not grant any time-based RSUs to our NEOs.
In 2020, we targeted roughly 25% of our NEO’s annual grant value to be performance-based RSU awards vesting
|
|
|
Element
|
| |
Purpose
|
| |
Key Characteristics
|
|
|
|
| |
|
| |
upon the Compensation Committee’s certification of achievement of pre-established performance goals discussed below.
From time to time, we may also use special RSU awards to encourage retention or for other purposes as determined by the Board. No such special RSUs were granted to NEOs in 2020.
|
|
|
Other Compensation
|
| |
Our executive officers participate in the same benefits offered to all other employees, which promote employee health and welfare and assist in attracting and retaining our executive officers.
|
| |
Indirect compensation element consisting of programs such as medical, vision, dental, life and accidental death, long-term care and disability insurance as well as a 401(k) plan with a Company matching contribution, and other plans and programs made available to all regular full-time employees.
|
|
|
Severance and Change in Control Benefits
|
| |
Serves our retention objectives by helping our named executive officers maintain continued focus and dedication to their responsibilities to maximize stockholder value, including in the event of a transaction that could result in a change in control of our Company.
|
| |
Provides protection in the event of a termination of employment under specified circumstances, including following a change in control of our Company as described below under “Potential Payments Upon Change in Control or Involuntary Termination.”
|
|
|
Name
|
| |
2020 Base Salary
|
| |
% Increase
from Prior
Year(1)
|
| |
2020 Target
Bonus
|
|
|
Ryan Spencer
|
| |
$515,000
|
| |
0%
|
| |
60%
|
|
|
David F. Novack
|
| |
$495,000
|
| |
0%
|
| |
55%
|
|
|
Michael S. Ostrach
|
| |
$464,398
|
| |
3%
|
| |
50%
|
|
|
Robert Janssen, M.D.
|
| |
$466,930
|
| |
3%
|
| |
50%
|
|
(1)
|
Because Messrs. Spencer and Novack received raises in connection with their promotions in late 2019, no additional increase was included as part of our 2020 merit cycle. Mr. Ostrach and Dr. Janssen received merit increases for 2020 based on prior year performance, and consistent with past practice.
|
|
Corporate Goal
|
| |
Weight
|
| |
Corporate Achievement
|
| |
Corporate Achievement Percentage
|
|
|
Advance HEPLISAV-B Sales
• Achieve 25% market share in field
targeted accounts.
• Achieve $28-30 million in
HEPLISAV-B full-year net sales.
• Convert at least one national account with >15,000 dose historical annual opportunity.
|
| |
50%
|
| |
The Compensation Committee determined that we achieved the goals in this category at an overall percentage of 106.5%. In determining this percentage, the Compensation Committee considered several factors, including:
• 26% market share achieved,
versus 20% one year prior.
• HEPLISAV-B net sales of $36.0 million despite overall
reduced vaccine utilization.
• Converted two national accounts.
|
| |
106.5%
|
|
|
Ensure long-term growth of HEPLISAV-B sales in the U.S.
• Stay on track to achieve policy
goals for 2021.
• Complete HBV-24 enrollment.
• Achieve 25% increase in HBsAg manufacturing yield.
|
| |
20%
|
| |
The Compensation Committee determined that we achieved the goal in this category at an overall percentage of 106.7%. In determining this percentage, the Compensation Committee considered several factors, including:
• Efforts have kept us on track for positive policy recommendation
from ACIP.
• HBV-24 enrollment completed on
time.
• Exceeded goal by increasing yield nearly 60% over baseline.
|
| |
106.7%
|
|
|
Corporate Goal
|
| |
Weight
|
| |
Corporate Achievement
|
| |
Corporate Achievement Percentage
|
|
|
Vaccine Business
• Develop ex-U.S. supply strategy.
• Respond to EMA review to support European approval by Q1 2021.
• Execute Pertussis development plan.
• Enter into at least two additional in-house development programs, external collaborations for CpG 1018, development partnerships or acquisitions.
|
| |
20%
|
| |
The Compensation Committee determined that we achieved the goal in this category at an overall percentage of 127%. In determining this percentage, the Compensation Committee considered several factors, including:
• Ex-US supply strategy goals met by successfully addressing identified business continuity risks, compliance and capacity requirements. Phased approach provides cost savings while maintaining flexibility in execution.
• Exceeded EMA goals, received CHMP positive opinion in Q4, tracked to the most aggressive timeline and managed a favorable outcome in European label negotiations.
• Pertussis development plan made significant progress ahead of schedule and continues on an appropriate track.
• Exceeded collaborations goal by entering into collaborations far in excess of our goal, which yielded 6 human clinical trials started so far, produced the Valneva commercial supply agreement and resulted in our first CpG 1018 revenue.
|
| |
127%
|
|
|
Financial
• End 2020 with specified cash and equivalents based on approved plan.
• Develop debt refinancing strategy.
• Increase organizational strength and capabilities through implementation of employee development, education, and communication programs to strengthen the connection and alignment to our objectives and to our vision leading to an increase in pride and ownership in our company and our results.
|
| |
10%
|
| |
The Compensation Committee determined that we achieved the goal in this category at an overall percentage of 111%. In determining this percentage, the Compensation Committee considered several factors, including:
• Cash and equivalents exceeded the goal significantly.
• Evaluated multiple debt refinancing options and established a strategy for refinancing, while continuing to watch market dynamics.
• Exceeded organizational goal by implementing multiple
|
| |
111%
|
|
|
Corporate Goal
|
| |
Weight
|
| |
Corporate Achievement
|
| |
Corporate Achievement Percentage
|
|
|
|
| |
|
| |
programs regarding employee recognition, leadership training, wellness, communications, employee development and training initiatives.
|
| |
|
|
|
Total
|
| |
100%
|
| |
|
| |
111%
|
|
|
Name
|
| |
Individual Goals
|
| |
Individual Achievement
|
| |
Individual Achievement Percentage
|
|
|
Michael S. Ostrach
|
| |
Finance:
• End 2020 with specified operating
capital based on approved plan.
• Develop debt refinancing strategy.
• Control net cash usage within budget.
• Determine whether to, and if necessary, implement, financial system upgrade or
replacement strategy.
• Add at least one additional sell side analyst, preferably bulge bracket.
Investor Relations:
• Develop patent strategies for specified
programs; file apps as appropriate.
• Reduce non-vaccine IP portfolio to minimum necessary to support
outboarding.
• Complete existing oncology opportunities.
|
| |
Met all goals, and exceeded goals for the year, as follows:
• Acted as a key contributor to our I/O
divestiture efforts.
• Acted as a key contributor to our coronavirus
collaborations.
• Managed net use of cash within approved operating budget with ending cash level above target.
|
| |
105%
|
|
|
Name
|
| |
Individual Goals
|
| |
Individual Achievement
|
| |
Individual Achievement Percentage
|
|
|
Robert Janssen, M.D.
|
| |
Advance HEPLISAV Clinical Studies and Regulatory Filings
• On track to achieve ACIP favorable policy recommendation in 2021:
− Provide 2 significant data updates to the working group.
− Write manuscript for effective seroprotection rates.
− Establish scientific data package to support preferential
recommendation.
• HBV-24: Complete enrollment
− Draft manuscript for 1Q21
submission
• HBV-26: complete interim analysis
and submit to FDA
• Respond to EMA review to support
approval by Q1 2021
• Submit Safety of CpG manuscript
Advance HEPLISAV Medical Affairs
Plan
• Create policy plan to facilitate ACIP decision-making for universal adult
hepatitis-B vaccination.
• Submit CEA manuscript.
• Approve at least two new ISRs
consistent in priority areas of interest.
• Engage and enlist three prioritized medical societies to recognize HEPLISAV-B.
Advance Vaccine Pipeline:
• Execute Pertussis development plan.
• Complete phase-1 enabling animal
studies for Pertussis
• FPI phase 1 Pertussis trial on track for Q1 2021 start (subject to animal
study results).
• Enter into either one additional in-house development program, one external collaboration for 1018, or one strategic development partnership
or acquisition.
• Support vaccine business development through scientific review of opportunities and engagement of key stakeholders.
Oncology
• Close out MEL-01.
• Complete I-SPY2 trial.
|
| |
Met all goals, and exceeded goals for the year, as
follows:
• Acted as a key technical contributor in coronavirus
collaborations
• Drove ongoing
Kaiser study
• Acted as key contributor in connection with our EU approval of HEPLISAV-B achieved on most aggressive timeline.
|
| |
105%
|
|
|
2020 Actual Annual Cash Incentive Paid
|
| |||||||||||||||||||||
|
|
| |
2020 Target Annual Cash Incentive
|
| |
Achievement of Corporate Goals
|
| |
Achievement of Individual Goals
|
| |
|
| |||||||||
|
Name
|
| |
% of Base
Salary
|
| |
$(1)
|
| |
% of Target
Annual Cash
Incentive
|
| |
$(1)
|
| |
% of Target
Annual Cash
Incentive
|
| |
$(1)
|
| |
Total(1)
|
|
|
Ryan Spencer(2)
|
| |
60%
|
| |
$309,000
|
| |
111%
|
| |
NA
|
| |
NA
|
| |
NA
|
| |
$342,990
|
|
|
David F. Novack(2)
|
| |
55%
|
| |
$272,250
|
| |
111%
|
| |
NA
|
| |
NA
|
| |
NA
|
| |
$302,198
|
|
|
Michael S. Ostrach(3)
|
| |
50%
|
| |
$232,199
|
| |
111%
|
| |
$206,192
|
| |
105%
|
| |
$48,762
|
| |
$254,955
|
|
|
Robert Janssen, M.D.
|
| |
50%
|
| |
$233,465
|
| |
111%
|
| |
$207,316
|
| |
105%
|
| |
$49,028
|
| |
$256,345
|
|
(1)
|
Amounts are rounded to nearest dollar.
|
(2)
|
Messrs. Spencer and Novack did not have separate individual goals, only corporate goals.
|
(3)
|
Notwithstanding the announcement of Mr. Ostrach’s planned retirement, Mr. Ostrach remained continuously employed with us through the determination date and was therefore eligible to receive his annual incentive award.
|
•
|
Achieve HEPLISAV-B net sales target of a specified dollar amount in a quarter prior to the end of 2022 (75%); and
|
•
|
Support efforts with respect to a favorable ACIP policy recommendation for HEPLISAV-B prior to the end of 2022 (25%).
|
|
Name
|
| |
Grant Date Fair Value
of February 2020
Time-Based Stock
Option Awards
|
| |
Grant Date Fair Value
of February 2020
Performance-Based
RSU Awards
|
|
|
Ryan Spencer
|
| |
$455,338
|
| |
$206,451
|
|
|
David F. Novack
|
| |
$523,742
|
| |
$189,700
|
|
|
Michael S. Ostrach
|
| |
$381,896
|
| |
$135,500
|
|
|
Robert Janssen, M.D.
|
| |
$381,896
|
| |
$135,500
|
|
|
Name and Principal Position
|
| |
Year
|
| |
Salary
|
| |
Stock
Awards(1)
|
| |
Option
Awards(2)
|
| |
Non-Equity
Incentive
Compensation(3)
|
| |
All Other
Compensation(4)
|
| |
Total
|
|
|
Ryan Spencer
Chief Executive
Officer and Director
|
| |
2020
|
| |
$515,000
|
| |
$206,451
|
| |
$455,338
|
| |
$342,990
|
| |
$2,000
|
| |
$1,521,779
|
|
|
2019
|
| |
$391,212
|
| |
$654,375
|
| |
$1,957,520
|
| |
$152,375
|
| |
$2,000
|
| |
$3,157,482
|
| |||
|
David F. Novack
President and Chief Operating Officer
|
| |
2020
|
| |
$495,000
|
| |
$189,700
|
| |
$523,742
|
| |
$302,198
|
| |
$2,000
|
| |
$1,512,640
|
|
|
2019
|
| |
$465,886
|
| |
$272,220
|
| |
$1,701,362
|
| |
$229,382
|
| |
$2,000
|
| |
$2,670,850
|
| |||
|
2018
|
| |
$401,700
|
| |
$—
|
| |
$1,083,000
|
| |
$210,892
|
| |
$2,000
|
| |
$1,697,592
|
| |||
|
Michael S. Ostrach
Former Senior Vice President, Chief
Financial Officer and
Chief Business Officer
|
| |
2020
|
| |
$464,398
|
| |
$135,500
|
| |
$381,896
|
| |
$254,955
|
| |
$2,000
|
| |
$1,238,749
|
|
|
2019
|
| |
$450,872
|
| |
$230,340
|
| |
$611,433
|
| |
$209,665
|
| |
$2,000
|
| |
$1,504,310
|
| |||
|
2018
|
| |
$439,875
|
| |
$—
|
| |
$2,904,000
|
| |
$216,639
|
| |
$2,000
|
| |
$3,562,514
|
| |||
|
Robert Janssen, M.D.
Senior Vice President and Chief
Medical Officer
|
| |
2020
|
| |
$466,930
|
| |
$135,500
|
| |
$381,896
|
| |
$256,345
|
| |
$2,000
|
| |
$1,242,671
|
|
|
2019
|
| |
$453,330
|
| |
$272,220
|
| |
$722,602
|
| |
$210,798
|
| |
$2,000
|
| |
$1,660,950
|
| |||
|
2018
|
| |
$438,000
|
| |
$—
|
| |
$1,083,000
|
| |
$216,810
|
| |
$2,000
|
| |
$1,739,810
|
|
(1)
|
Represents the aggregate grant date fair value of RSUs granted in the fiscal year in accordance with ASC 718. See note 15 of our “Notes to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 25, 2021 for a discussion of assumptions we made in determining the compensation costs included in this column. With regard to awards with performance-based vesting, the grant date fair value assumes the highest level of achievement had been met. For further discussion of these performance-based RSUs, see the section entitled “Compensation Discussion and Analysis – 2020 Executive Compensation Decisions – Long-Term Equity Incentive Awards.”
|
(2)
|
Represents the aggregate grant date fair value of option awards granted in the fiscal year in accordance with ASC 718. See note 15 of our “Notes to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 25, 2021 for a discussion of assumptions we made in determining the compensation costs included in this column.
|
(3)
|
Represents the annual cash incentive bonuses earned pursuant to our annual cash incentive bonus plan for services rendered in the fiscal year. For further discussion see the section entitled “Compensation Discussion and Analysis – 2020 Executive Compensation Decisions – 2020 Annual Incentive Program – Structure, Goals and Payout Decision.”
|
(4)
|
Represents $2,000 401(k) matching contribution for each NEO made by the Company in the fiscal year.
|
|
Name
|
| |
Grant Date
|
| |
Date of Board
or
Compensation
Committee
Action to Grant
Award
|
| |
Estimated
Future
Payouts
Under
Non-Equity
Incentive
Plan
Awards
Target(1)
($)
|
| |
Estimated
Future
Payouts
Under
Equity
Incentive
Plan
Awards
Target(2)
(#)
|
| |
All Other
Stock
Awards:
Number of
Shares of
Stock
or Units
(#)
|
| |
All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)
|
| |
Exercise
or Base
Price of
Option
Awards
($/Share)
|
| |
Grant Date
Fair Value
of RSU and
Option
Awards(3) ($)
|
|
|
Ryan Spencer
|
| |
—
|
| |
—
|
| |
$309,000
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
2/13/2020
|
| |
2/13/2020
|
| |
|
| |
—
|
| |
—
|
| |
130,000
|
| |
$5.22
|
| |
$455,338
|
| |||
|
2/13/2020
|
| |
2/13/2020
|
| |
|
| |
39,550
|
| |
—
|
| |
—
|
| |
—
|
| |
$206,451
|
| |||
|
David F. Novack
|
| |
—
|
| |
—
|
| |
$272,250
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
—
|
| |
—
|
| |
144,000
|
| |
$5.42
|
| |
$523,742
|
| |||
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
35,000
|
| |
—
|
| |
—
|
| |
—
|
| |
$189,700
|
| |||
|
Michael S. Ostrach
|
| |
—
|
| |
—
|
| |
$232,199
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
—
|
| |
—
|
| |
105,000
|
| |
$5.42
|
| |
$381,896
|
| |||
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
25,000
|
| |
—
|
| |
—
|
| |
—
|
| |
$135,500
|
| |||
|
Robert Janssen, M.D.
|
| |
—
|
| |
—
|
| |
$233,465
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
—
|
| |
—
|
| |
105,000
|
| |
$5.42
|
| |
$381,896
|
| |||
|
2/12/2020
|
| |
2/12/2020
|
| |
|
| |
25,000
|
| |
—
|
| |
—
|
| |
—
|
| |
$135,500
|
|
(1)
|
Represents the target cash incentive award in fiscal year 2020 as further described under “Compensation Discussion and Analysis – Elements of Executive Compensation”; our annual cash incentive program does not specify minimum or maximum levels.
|
(2)
|
Represents the number of PSUs granted in the fiscal year that are subject to performance-based vesting, as described in the “Compensation Discussion and Analysis.”
|
(3)
|
Represents the aggregate grant date fair value of options granted in fiscal year 2020 in accordance with ASC 718. See Note 15 of our “Notes to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 25, 2021 for a discussion of the assumptions we made in determining the compensation costs included in this column. With regard to awards with performance-based vesting, the grant date fair value assumes the highest level of achievement had been met, as reported in the “Summary Compensation Table.” For further discussion of these performance-based RSUs, see the section entitled “Compensation Discussion and Analysis – 2020 Executive Compensation Decisions – Long-Term Equity Incentive Awards.”
|
|
|
| |
|
| |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||
|
Name
|
| |
|
| |
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
| |
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
| |
Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
|
| |
Option
Exercise
Price
($)
|
| |
Vesting
Commencement
Date
|
| |
Option
Expiration
Date
|
| |
Number of
Shares or
Units that
Have Not
Vested (#)
|
| |
Market
Value
of Stock
that
Have Not
Vested ($)(1)
|
| |
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares or
Other
Rights
that Have
Not
Vested (#)
|
| |
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares or
Other
Rights that
Have Not
Vested ($)
|
|
|
Ryan Spencer
|
| |
|
| |
4,500
|
| |
—
|
| |
—
|
| |
$31.40
|
| |
1/6/2011
|
| |
1/5/2021
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
4,500
|
| |
—
|
| |
—
|
| |
$36.80
|
| |
2/1/2012
|
| |
1/31/2022
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
2,000
|
| |
—
|
| |
—
|
| |
$42.60
|
| |
10/22/2012
|
| |
10/21/2022
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
5,250
|
| |
—
|
| |
—
|
| |
$30.60
|
| |
2/6/2013
|
| |
2/5/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
3,500
|
| |
—
|
| |
—
|
| |
$16.70
|
| |
2/6/2014
|
| |
2/5/2024
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
9,500
|
| |
—
|
| |
—
|
| |
$16.00
|
| |
2/9/2015
|
| |
2/8/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
2,000
|
| |
—
|
| |
—
|
| |
$30.49
|
| |
9/10/2015
|
| |
9/9/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
52,888
|
| |
3,112
|
| |
—
|
| |
$16.45
|
| |
2/1/2018
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
25,000
|
| |
25,000
|
| |
—
|
| |
$3.81
|
| |
6/14/2019
|
| |
6/13/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
133,332
|
| |
266,668
|
| |
—
|
| |
$6.80
|
| |
12/16/2019
|
| |
12/15/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(6)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
41,666
|
| |
$185,414
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
—
|
| |
130,000
|
| |
—
|
| |
$5.22
|
| |
2/13/2020
|
| |
2/12/2027
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(7)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
|
| |
|
| |
39,550
|
| |
$175,998
|
|
|
David F. Novack
|
| |
|
| |
30,000
|
| |
—
|
| |
—
|
| |
$21.40
|
| |
3/25/2013
|
| |
3/24/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
22,000
|
| |
—
|
| |
—
|
| |
$17.10
|
| |
2/4/2014
|
| |
2/3/2024
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
75,000
|
| |
—
|
| |
—
|
| |
$16.00
|
| |
2/9/2015
|
| |
2/8/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
64,000
|
| |
—
|
| |
—
|
| |
$21.99
|
| |
2/4/2016
|
| |
2/3/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
75,555
|
| |
4,445
|
| |
—
|
| |
$16.45
|
| |
2/1/2018
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(3)
|
| |
18,000
|
| |
—
|
| |
—
|
| |
$16.45
|
| |
—
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
63,555
|
| |
40,445
|
| |
—
|
| |
$10.47
|
| |
2/22/2019
|
| |
2/21/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
12,500
|
| |
12,500
|
| |
—
|
| |
$3.81
|
| |
6/14/2019
|
| |
6/13/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
66,666
|
| |
133,334
|
| |
—
|
| |
$6.80
|
| |
12/16/2019
|
| |
12/15/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
—
|
| |
144,000
|
| |
—
|
| |
$5.42
|
| |
2/12/2020
|
| |
2/11/2027
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(5)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
|
| |
|
| |
35,000
|
| |
$155,750
|
|
|
Michael S. Ostrach
|
| |
|
| |
25,000
|
| |
—
|
| |
—
|
| |
$31.40
|
| |
1/6/2011
|
| |
1/5/2021
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
18,000
|
| |
—
|
| |
—
|
| |
$34.80
|
| |
1/31/2012
|
| |
1/30/2022
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
20,000
|
| |
—
|
| |
—
|
| |
$30.80
|
| |
2/5/2013
|
| |
2/4/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
27,000
|
| |
—
|
| |
—
|
| |
$17.10
|
| |
2/4/2014
|
| |
2/3/2024
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
67,000
|
| |
—
|
| |
—
|
| |
$16.00
|
| |
2/9/2015
|
| |
2/8/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
29,000
|
| |
—
|
| |
—
|
| |
$28.45
|
| |
8/27/2015
|
| |
8/26/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
84,000
|
| |
—
|
| |
—
|
| |
$21.99
|
| |
2/4/2016
|
| |
2/3/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
71,695
|
| |
8,305
|
| |
—
|
| |
$16.45
|
| |
2/1/2018
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(3)
|
| |
18,000
|
| |
—
|
| |
—
|
| |
$16.45
|
| |
—
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(4)
|
| |
75,000
|
| |
75,000
|
| |
—
|
| |
$18.40
|
| |
3/21/2018
|
| |
3/20/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
53,778
|
| |
34,222
|
| |
—
|
| |
$10.47
|
| |
2/22/2019
|
| |
2/21/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
—
|
| |
105,000
|
| |
—
|
| |
$5.42
|
| |
2/12/2020
|
| |
2/11/2027
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(5)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
|
| |
|
| |
25,000
|
| |
$111,250
|
|
|
Robert Janssen, M.D.
|
| |
|
| |
2,250
|
| |
—
|
| |
—
|
| |
$31.40
|
| |
1/6/2011
|
| |
1/5/2021
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
2,500
|
| |
—
|
| |
—
|
| |
$36.80
|
| |
2/1/2012
|
| |
1/31/2022
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
15,000
|
| |
—
|
| |
—
|
| |
$41.40
|
| |
10/31/2012
|
| |
10/30/2022
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
18,000
|
| |
—
|
| |
—
|
| |
$17.10
|
| |
2/4/2014
|
| |
2/3/2024
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
56,000
|
| |
—
|
| |
—
|
| |
$16.00
|
| |
2/9/2015
|
| |
2/8/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
| |
80,000
|
| |
—
|
| |
—
|
| |
$21.99
|
| |
2/4/2016
|
| |
2/3/2023
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
75,555
|
| |
4,445
|
| |
—
|
| |
$16.45
|
| |
2/1/2018
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(3)
|
| |
18,000
|
| |
—
|
| |
—
|
| |
$16.45
|
| |
—
|
| |
1/31/2025
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
63,555
|
| |
40,445
|
| |
—
|
| |
$10.47
|
| |
2/22/2019
|
| |
2/21/2026
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(2)
|
| |
—
|
| |
105,000
|
| |
—
|
| |
$5.42
|
| |
2/12/2020
|
| |
2/11/2027
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
(5)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
|
| |
|
| |
25,000
|
| |
$111,250
|
|
(1)
|
Represents the aggregate fair value of RSUs based on the last closing price per share as of December 31, 2020 of $4.45.
|
(2)
|
Options vest at the rate of 1/3rd of the shares on the first anniversary of the vesting commencement date, with 1/36th of the total number of shares vesting each month thereafter.
|
(3)
|
Options fully vested upon achievement of performance goals.
|
(4)
|
Options vest 50% on March 21, 2020 and the remainder will vest on March 21, 2021.
|
(5)
|
This RSU was granted on February 12, 2020 and are subject to performance-based vesting.
|
(6)
|
This RSU was granted on February 22, 2019 prior to Mr. Spencer becoming an NEO. The RSU vests over three years with one-third vesting on each annual anniversary date.
|
(7)
|
This RSU was granted on February 13, 2020 and are subject to performance-based vesting.
|
|
|
| |
Option Awards
|
| |
Stock Awards
|
| ||||||
|
Name
|
| |
Number of Shares
Acquired on
Exercise (#)
|
| |
Value Realized
on Exercise
($)
|
| |
Number of Shares
Acquired on
Vesting (#)
|
| |
Value Realized
on Vesting
($)(1)
|
|
|
Ryan Spencer
|
| |
—
|
| |
—
|
| |
33,646
|
| |
$89,498
|
|
|
David F. Novack
|
| |
—
|
| |
—
|
| |
79,763
|
| |
$323,517
|
|
|
Michael S. Ostrach
|
| |
—
|
| |
—
|
| |
80,304
|
| |
$213,609
|
|
|
Robert Janssen, M.D.
|
| |
—
|
| |
—
|
| |
81,375
|
| |
$216,458
|
|
(1)
|
The value realized on vesting is determined by multiplying the number of shares of stock by the market value of the underlying shares as reported by the Nasdaq Capital Market on the vesting date.
|
•
|
a lump-sum cash payment equal to a specified number of months (21 months for Mr. Spencer, 18 months for Mr. Novack, and 15 months for our other NEOs) of the executive’s then-effective annual base salary;
|
•
|
a lump-sum cash payment equal to a specified percentage of the NEO’s target annual variable cash compensation (175% of such target for Mr. Spencer, 150% for Mr. Novack, and 125% of such target for our other NEOs) for the year of termination;
|
•
|
cash payments equal to the value of the applicable COBRA premiums for up to the same number of months as the NEO receives in base salary, payable in a single lump sum, as set forth in the first bullet (the “COBRA Payment”);
|
•
|
acceleration of vesting of all outstanding equity awards at the time of such termination; and
|
•
|
the extension of exercisability of all stock options to purchase the Company’s common stock for a period of 3 years following termination of employment (but in any event not beyond each option’s expiration date).
|
|
Name
|
| |
Severance
Payment
|
| |
Continuation
of Benefits
|
| |
Value of
Accelerated
Stock Awards(1)
|
| |
Total
|
|
|
Ryan Spencer
|
| |
$1,442,000
|
| |
$31,217
|
| |
$377,411
|
| |
$1,850,628
|
|
|
David F. Novack
|
| |
$1,150,875
|
| |
$41,356
|
| |
$163,750
|
| |
$1,355,981
|
|
|
Michael S. Ostrach
|
| |
$870,746
|
| |
$41,356
|
| |
$111,250
|
| |
$1,023,352
|
|
|
Robert Janssen, M.D.
|
| |
$875,494
|
| |
$27,597
|
| |
$111,250
|
| |
$1,014,341
|
|
(1)
|
Represents the value of accelerated vesting of equity awards if the event took place on December 31, 2020. The value for RSUs is calculated based on the closing price per share on December 31, 2020. The value for stock option awards is calculated based on the “spread” between the closing price per share on December 31, 2020 of $4.45 and the exercise price of the vested awards, to the extent such vested awards were “in the money.”
|
•
|
a lump-sum cash payment equal to the specified number of months (ranging from 12 to 21) of the executive’s then-effective annual base salary;
|
•
|
the COBRA Payment; and
|
•
|
for Messrs. Spencer and Novack, the extension of exercisability of all vested stock options to purchase the Company’s common stock for a period of 18 months, and 15 months, respectively (and 12 months for all other NEOs) following termination of employment (but in any event not beyond each option’s expiration date).
|
|
Name
|
| |
Severance
Payment
|
| |
Continuation
of Benefits
|
| |
Value of
Accelerated
Stock Awards
|
| |
Total
|
|
|
Ryan Spencer
|
| |
$772,500
|
| |
$26,757
|
| |
$—
|
| |
$799,257
|
|
|
David F. Novack
|
| |
$618,750
|
| |
$34,463
|
| |
$—
|
| |
$653,213
|
|
|
Michael S. Ostrach
|
| |
$696,597
|
| |
$41,356
|
| |
$—
|
| |
$737,953
|
|
|
Robert Janssen, M.D.
|
| |
$466,930
|
| |
$22,078
|
| |
$—
|
| |
$489,008
|
|
•
|
To determine our total population of employees, we included all full-time, part-time, and temporary employees as of December 31, 2020.
|
•
|
To identify our median employee from our employee population, we calculated the aggregate amount of each employee’s 2020 base salary (using a reasonable estimate of the hours worked and overtime actually paid during 2020 for hourly employees and actual salary paid for our remaining employees), the actual value of annual cash incentive awards earned in 2020, and the value of equity awards granted in 2020 using the same methodology we use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table.
|
•
|
In making this determination, we annualized the compensation elements listed above of employees who were employed by us for less than the entire calendar year.
|
•
|
Compensation paid in foreign currencies was converted to U.S. dollars based on exchange rates in effect on December 31, 2020.
|
•
|
Aligning the long-term interests of stockholders and directors; and
|
•
|
Compensating directors appropriately and adequately for their time, effort and experience
|
•
|
A $65,000 annual retainer for service as chairman of the Board or, alternatively, a $40,000 annual retainer for service as a member of the Board.
|
•
|
A $20,000 annual retainer for the Chair of the Audit Committee and a $10,000 annual retainer for each additional member of the Audit Committee.
|
•
|
A $15,000 annual retainer for the Chair of the Compensation Committee and a $7,000 annual retainer for each additional member of the Compensation Committee.
|
•
|
A $10,000 annual retainer for the Chair of the Nominating and Corporate Governance Committee and $5,000 annual retainer for each additional member of the Nominating and Corporate Governance Committee.
|
•
|
Each new director automatically received an initial equity award (“Initial Grant”) consisting of a non-qualified stock option to purchase 50,000 shares of our common stock upon the date each such person is elected or appointed to the Board.
|
•
|
On the date of each annual meeting of the Company’s stockholders, each non-employee director also automatically received a subsequent equity award (“Subsequent Grant”), consisting of a non-qualified stock option to purchase 25,000 shares of Dynavax common stock. However, the non-employee director’s first Subsequent Grant was reduced to –
|
○
|
75% of the Subsequent Grant, or 18,750 shares, if the service period from the non-employee director’s initial election date to the annual meeting was between 7 and 10 months;
|
○
|
50% of the Subsequent Grant, or 12,500 shares, if the service period from the non-employee director’s initial election date to the annual meeting was between 4 and 7 months; and
|
○
|
25% of the Subsequent Grant, or 6,250 shares, if the service period from the non-employee director’s initial election date to the annual meeting was between 1 and 4 months.
|
|
Name
|
| |
Fees Earned or
Paid in Cash(1)
|
| |
Option
Awards(2)(3)
|
| |
Total
|
|
|
Andrew A. F. Hack, M.D., Ph.D.
|
| |
$85,000
|
| |
$62,376
|
| |
$147,376
|
|
|
Laura Brege(4)
|
| |
$7,500
|
| |
—
|
| |
$7,500
|
|
|
Francis R. Cano, Ph.D.
|
| |
$49,212
|
| |
$83,168
|
| |
$132,380
|
|
|
Dennis A Carson, M.D.(4)
|
| |
—
|
| |
—
|
| |
—
|
|
|
Julia M. Eastland
|
| |
$22,802
|
| |
$393,570
|
| |
$416,372
|
|
|
Daniel L. Kisner, M.D.
|
| |
$57,000
|
| |
$83,168
|
| |
$140,168
|
|
|
Brent MacGregor
|
| |
$20,234
|
| |
$393,570
|
| |
$413,804
|
|
|
Arnold L. Oronsky, Ph.D.
|
| |
$36,016
|
| |
$83,168
|
| |
$119,184
|
|
|
Peter R. Paradiso
|
| |
$10,769
|
| |
$157,580
|
| |
$168,349
|
|
|
Peggy V. Phillips
|
| |
$65,000
|
| |
$83,168
|
| |
$148,168
|
|
|
Natale Ricciardi
|
| |
$45,796
|
| |
$83,168
|
| |
$128,964
|
|
(1)
|
Consists of fees earned or paid in 2020 for Board and committee membership as described above.
|
(2)
|
Represents the aggregate grant date fair value of stock options granted in the fiscal year in accordance with ASC 718. See note 15 of our “Notes to Consolidated Financial Statements” in our annual report on Form 10-K filed with the SEC on February 25, 2021, for a discussion of assumptions we made in determining the compensation costs included in this column.
|
(3)
|
As of December 31, 2020, each non-employee director held stock options to purchase the following number of shares of our common stock. Dr. Hack held options to purchase 33,750 shares of our common stock. Dr. Cano held options to purchase 92,550 shares of our common stock. Ms. Eastland held options to purchase 50,000 shares of our common stock. Dr. Kisner held options to purchase 96,950 shares of our common stock. Mr. MacGregor held options to purchase 50,000 shares of our common stock. Dr. Oronsky held options to purchase 71,950 shares of our common stock. Mr. Paradiso held options to purchase 50,000 shares of our common stock. Ms. Phillips held options to purchase 96,950 shares of our common stock; and Mr. Ricciardi held options to purchase 82,750 shares of our common stock.
|
(4)
|
Ms. Brege and Dr. Carson left our Board in February 2020.
|
|
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
|
|
|
Andrew A. F. Hack, M.D., Ph.D.(1)
|
| |
X*
|
| |
X*
|
| |
|
|
|
Laura Brege(1)
|
| |
X*
|
| |
|
| |
|
|
|
Dennis A. Carson, M.D.
|
| |
|
| |
|
| |
|
|
|
Julie Eastland(1)
|
| |
X
|
| |
|
| |
|
|
|
Arnold L. Oronsky, Ph.D.(1)
|
| |
X
|
| |
|
| |
|
|
|
Brent MacGregor(2)
|
| |
X
|
| |
|
| |
|
|
|
Daniel L. Kisner, M.D.
|
| |
|
| |
X
|
| |
X*
|
|
|
Francis R. Cano, Ph.D.(3)
|
| |
|
| |
X
|
| |
X
|
|
|
Natale Ricciardi(2)(3)
|
| |
X
|
| |
X
|
| |
|
|
|
Peggy V. Phillips
|
| |
X
|
| |
X*
|
| |
|
|
|
Total Members
|
| |
3
|
| |
3
|
| |
3
|
|
|
Total Meetings
|
| |
4
|
| |
8
|
| |
8
|
|
*
|
Committee Chairperson
|
(1)
|
Ms. Brege served as chairperson of our Audit Committee until February 2020 when she left our Board, and Dr. Hack became chairperson. Dr. Oronsky served on our Audit Committee until August of 2020 at which time Ms. Eastland was appointed to the Audit Committee and Dr. Oronsky rotated off.
|
(2)
|
Mr. MacGregor was appointed to our Nominating and Corporate Governance Committee in August 2020 at which time Mr. Ricciardi rotated off.
|
(3)
|
Mr. Ricciardi was appointed to our Compensation Committee in August 2020 at which time Dr. Cano rotated off.
|
•
|
review and monitor the policies and procedures adopted by the Company to fulfill its responsibilities regarding the fair and accurate presentation of the Company’s financial statements;
|
•
|
appoint, compensate, and oversee the work of the Company’s independent registered public accounting firm;
|
•
|
approve and monitor all audit and non-audit services performed by the Company’s independent registered public accounting firm;
|
•
|
investigate, review and report the propriety and ethical implications of any transactions between the Company and any related persons;
|
•
|
consult and discuss with management and the independent registered public accounting firm regarding the effectiveness of the Company’s internal controls over financial reporting;
|
•
|
establish procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters;
|
•
|
oversee the Company’s healthcare compliance program;
|
•
|
review and evaluate the Company’s accounting principles and systems of internal controls; and
|
•
|
review and discuss the disclosure of the Company’s annual audited financial statements and quarterly financial statements, including reviewing the Company’s disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
|
•
|
discussed with management and Ernst & Young management’s continued testing and evaluation of its system of internal control over financial reporting. We also reviewed Ernst & Young’s Report of Independent Registered Public Accounting Firm included in the Annual Report on Form 10-K, or Annual Report, related to its audit of the effectiveness of the Company’s internal control over financial reporting;
|
•
|
reviewed and discussed with management and Ernst & Young the annual audited financial statements before filing the Annual Report with the SEC, addressing the acceptability of the Company’s accounting principles and such other matters as applicable auditing standards require us to discuss; the
|
•
|
reviewed and discussed with management and Ernst & Young the Company’s quarterly unaudited financial statements before the issuance of its quarterly financial results press releases and the filing of its Quarterly Reports on Form 10-Q with the SEC;
|
•
|
discussed with management and Ernst & Young significant financial reporting matters, including liquidity and capital requirements, and the accounting for significant transactions;
|
•
|
appointed and oversaw the work and compensation of Ernst & Young, including the review of engagement agreement terms;
|
•
|
reviewed and provided guidance with respect to the external audit and the Company’s relationship with Ernst & Young by (1) reviewing Ernst & Young’s proposed audit scope, approach, compensation and independence; (2) obtaining written statements and disclosures from Ernst & Young regarding relationships and services with the Company which may impact independence as required by applicable requirements of the PCAOB regarding the accounting firm’s independence; (3) discussing with Ernst & Young the financial statements and audit findings, including any significant adjustments, management judgments and accounting estimates, significant new accounting policies and whether there were disagreements with management; and (4) obtaining assurance from Ernst & Young that the requirements of Section 10A of the Exchange Act have been met; and
|
•
|
reviewed, in conjunction with the Company’s legal counsel, all legal matters that could have a significant impact on the Company’s financial statements or compliance policies.
|
•
|
Annually review and approve the Company’s corporate goals and objectives relevant to Chief Executive Officer compensation, evaluate the Chief Executive Officer’s performance in light of such goals and objectives, and recommend to the Board the Chief Executive Officer’s compensation level based on this evaluation. In determining the long-term incentive component of the Chief Executive Officer’s compensation, the Compensation Committee will consider the Company’s performance and relative stockholder return, the value of similar incentive awards to Chief Executive Officers at comparable companies, and the awards given to the Company’s Chief Executive Officer in past years;
|
•
|
annually review and make recommendations to the Board with respect to incentive compensation plans and equity-based plans;
|
•
|
annually review Director compensation and make recommendation to the Board;
|
•
|
administer the Company’s incentive-compensation plans and equity-based plans as in effect and as adopted from time to time by the Board provided that the Board shall retain the authority to interpret such plans;
|
•
|
annually review and approve for the Company’s executive officers as defined in Rule 16a-1(f) of the Exchange Act: i) annual base salary levels; ii) annual incentive compensation levels; iii) long-term incentive compensation levels; and iv) employment agreements, severance agreements, change of control agreements/provisions and any other compensatory arrangements, in each case as, when and if appropriate;
|
•
|
make regular reports to the Board; and
|
•
|
perform such other functions and have such other powers consistent with the Compensation Committee Charter, the Company’s Bylaws and governing laws as the Compensation Committee or the Board may deem appropriate.
|
|
Name and Address of Beneficial Holder
|
| |
Number of
Shares(2)
|
| |
Percent of Shares
Beneficially
Owned(3)
|
|
|
5% Stockholders
|
| |
|
| |
|
|
|
Federated Hermes, Inc.(4)
|
| |
12,521,800
|
| |
11.31%
|
|
|
State Street Corporation(5)
|
| |
10,887,296
|
| |
9.88%
|
|
|
Bain Capital Life Sciences Fund, L.P.(6)
|
| |
10,895,773
|
| |
9.99%
|
|
|
BlackRock, Inc.(7)
|
| |
8,188,156
|
| |
7.40%
|
|
|
Chicago Capital LLC(8)
|
| |
5,782,610
|
| |
5.25%
|
|
|
NEOs and Directors(1)
|
| |
|
| |
|
|
|
Ryan Spencer(9)
|
| |
404,417
|
| |
*
|
|
|
David F. Novack(10)
|
| |
650,203
|
| |
*
|
|
|
Michael S. Ostrach(11)
|
| |
709,194
|
| |
*
|
|
|
Kelly MacDonald
|
| |
—
|
| |
*
|
|
|
Robert Janssen, M.D.(12)
|
| |
508,278
|
| |
*
|
|
|
Francis R. Cano, Ph.D.(13)
|
| |
88,384
|
| |
*
|
|
|
Julia M. Eastland
|
| |
—
|
| |
*
|
|
|
Andrew A. F. Hack, M.D., Ph.D.(14)
|
| |
10,895,773
|
| |
9.99%
|
|
|
Daniel L. Kisner, M.D.(15)
|
| |
73,450
|
| |
*
|
|
|
Brent MacGregor
|
| |
—
|
| |
*
|
|
|
Peter R. Paradiso(16)
|
| |
3,000
|
| |
*
|
|
|
Peggy V. Phillips(17)
|
| |
106,584
|
| |
*
|
|
|
Natale Ricciardi(18)
|
| |
57,750
|
| |
*
|
|
|
All executive officers and directors as a group (13 persons)(19)
|
| |
13,497,033
|
| |
11.77%
|
|
**
|
Less than one percent.
|
(1)
|
The address of each of the NEOs and directors is c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California 94608.
|
(2)
|
To our knowledge, except as set forth in the footnotes to this table, and subject to applicable community property laws, each person named in this table has sole voting and investment power with respect to the shares set forth opposite such person’s name.
|
(3)
|
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the securities. Shares of our common stock subject to options currently exercisable or that will become exercisable within 60 days after January 31, 2021, are deemed outstanding for computing the percentage of the person holding such options but are not deemed outstanding for computing the percentage of any other person. Applicable percentages are based on 110,189,859 shares of our common stock outstanding as of January 31, 2021, adjusted as required by the rules of the SEC.
|
(4)
|
This information is based solely on Schedule 13G/A filed by Federated Hermes, Inc. on February 12, 2021, with the SEC. Federated Hermes, Inc. beneficially owns 12,521,800 shares and has sole dispositive or sole voting power. The address of the principal business and office of Federated Hermes, Inc. is, 1001 Liberty Avenue, Pittsburgh, PA 15222-3779. The Schedule 13G/A provides information only as of December 31, 2020 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December 31, 2020 and January 31, 2021.
|
(5)
|
This information is based solely on a Schedule 13G filed by State Street Corporation on February 11, 2021, with the SEC. State Street Corp. beneficially owns 10,887,296 shares and has no sole dispositive or sole voting power. The address of the principal business and office of State Street Corp. is, One Lincoln Street, Boston, MA 02111. The Schedule 13G provides information only as of December 31, 2020, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December 31, 2020 and January 31, 2021.
|
(6)
|
This information is based primarily on Schedule 13D/A filed by Bain Capital Life Sciences Fund, L.P. on May 28, 2020, with the SEC. Bain Capital Life Sciences Fund L.P. holds 7,733,411 shares of common stock, 3,756 shares of Series B preferred stock and warrants to purchase 2,645,566 shares of common stock. BCIP Life Sciences Associates, LP holds 791,589 shares of common stock, 384 shares of Series B preferred stock and warrants to purchase 270,684 shares of common stock. Also includes 5,000 options held by Dr. Hack for the benefit of Bain Capital Life Sciences Fund, L.P. As a result of the Beneficial Ownership Blocker, beneficial ownership is capped at 9.99% of the outstanding common stock of the issuer. The address of the principal business and office of Bain Capital Life Sciences Fund, L.P. is, 200 Clarendon Street, Boston, MA 02116. The Schedule 13G provides information only as of May 27, 2020.
|
(7)
|
This information is based solely on Schedule 13G/A filed by BlackRock, Inc. on January 29, 2021 with the SEC. BlackRock, Inc. beneficially owns and has sole dispositive power over 8,188,156 shares of common stock, of which 7,975,325 shares are held with sole voting power. The address of the principal business and office of BlackRock, Inc. is, 55 East 52nd Street, New York, NY 10055. The Schedule 13G provides information only as of December 31, 2020 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December 31, 2020 and January 31, 2021.
|
(8)
|
This information is based solely on Schedule 13G filed by Chicago Capital LLC on February 23, 2021, with the SEC. Chicago Capital LLC beneficially owns 5,782,610 shares and has sole dispositive or sole voting power. The address of the principal business and office of Chicago Capital LLC is, 135 South LaSalle Street, Suite 3450, Chicago, IL 60603. The Schedule 13G provides information only as of December 31, 2020 and consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December 31, 2020 and January 31, 2021.
|
(9)
|
Consists of 58,059 shares of common stock owned directly by Mr. Spencer, restricted stock awards to be converted into 20,833 shares of common stock within 60 days of January 31, 2021 and options to purchase 325,525 shares of common stock exercisable within 60 days of January 31, 2021.
|
(10)
|
Consists of 134,899 shares of common stock owned directly by Mr. Novack, warrants to purchase 4,167 shares of common stock and options to purchase 511,137 shares of common stock exercisable within 60 days of January 31, 2021.
|
(11)
|
Consists of 117,167 shares of common stock owned directly by Mr. Ostrach and options to purchase 592,027 shares of common stock exercisable within 60 days of January 31, 2021.
|
(12)
|
Consists of 128,640 shares of common stock owned directly by Dr. Janssen and options to purchase 379,638 shares of common stock exercisable within 60 days of January 31, 2021.
|
(13)
|
Consists of 16,667 shares of common stock owned directly by Dr. Cano, warrants to purchase 4,167 shares of common stock and options to purchase 67,550 shares of common stock exercisable within 60 days of January 31, 2021.
|
(14)
|
This information is based primarily on Schedule 13D/A filed by Bain Capital Life Sciences Fund, L.P. on May 28, 2020, with the SEC. Bain Capital Life Sciences Fund L.P. holds 7,733,411 shares of common stock, 3,756 shares of Series B preferred stock and warrants to purchase 2,645,566 shares of common stock. BCIP Life Sciences Associates, LP holds 791,589 shares of common stock, 384 shares of Series B preferred stock and warrants to purchase 270,684 shares of common stock. Also includes 5,000 options held by Dr. Hack for the benefit of Bain Capital Life Sciences Fund, L.P. As a result of the Beneficial Ownership Blocker, beneficial ownership is capped at 9.99% of the outstanding common stock of the issuer. Bain Capital Life Sciences Investors, LLC (“BCLSI”) is the ultimate general partner of BCLS and governs the investment strategy and decision making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of these relationships, Dr. Hack may be deemed to share voting and dispositive power with respect to shares of common stock held by the Bain Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
|
(15)
|
Consists of 1,500 shares of common stock owned directly by Dr. Kisner and options to purchase 71,950 shares of common stock exercisable within 60 days of January 31, 2021.
|
(16)
|
Consists of 3,000 shares of common stock owned directly by Mr. Paradiso.
|
(17)
|
Consists of 30,468 shares of common stock owned directly by Ms. Phillips, warrants to purchase 4,166 shares of common stock and options to purchase 71,950 shares of common stock exercisable within 60 days of January 31, 2021.
|
(18)
|
Consists of options to purchase 57,750 shares of common stock exercisable within 60 days of January 31, 2021.
|
(19)
|
Total number of shares includes common stock, Series B preferred stock and warrants to purchase common stock, in aggregate, held as of January 31, 2021, by our executive officers and directors and entities affiliated with such executive officers and directors. Also includes restricted stock awards to be converted into 20,833 shares of common stock within 60 days of January 31, 2021 and options to purchase 2,082,527 shares of common stock exercisable within 60 days of January 31, 2021.
|
|
| |
By Order of the Board of Directors
|
|
| |
|
|
| |
Kelly MacDonald
Chief Financial Officer
|
April 16, 2021
|
| |
|
1.
|
GENERAL; PURPOSE.
|
2.
|
ADMINISTRATION.
|
3.
|
SHARES OF COMMON STOCK SUBJECT TO THE PLAN.
|
4.
|
GRANT OF PURCHASE RIGHTS; OFFERING.
|
5.
|
ELIGIBILITY.
|
1.
|
The 500,000 shares approved at the Company’s 2014 Annual Meeting of Stockholders were adjusted to 50,000 shares pursuant to a 1-for-10 reverse stock split effective November 7, 2014.
|
6.
|
PURCHASE RIGHTS; PURCHASE PRICE.
|
7.
|
PARTICIPATION; WITHDRAWAL; TERMINATION.
|
8.
|
EXERCISE OF PURCHASE RIGHTS.
|
9.
|
COVENANTS OF THE COMPANY.
|
10.
|
DESIGNATION OF BENEFICIARY.
|
11.
|
ADJUSTMENTS UPON CHANGES IN COMMON STOCK; CORPORATE TRANSACTIONS.
|
12.
|
AMENDMENT, TERMINATION OR SUSPENSION OF THE PLAN.
|
13.
|
EFFECTIVE DATE OF PLAN.
|
14.
|
MISCELLANEOUS PROVISIONS.
|
15.
|
DEFINITIONS.
|